{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T07:57:10Z","timestamp":1783065430971,"version":"3.54.6"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T00:00:00Z","timestamp":1644019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T00:00:00Z","timestamp":1644019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Mayo Transform the Practice Grant"},{"DOI":"10.13039\/100014535","name":"Center for Individualized Medicine, Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014535","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Desert Mountain Members\u2019 CARE Foundation"},{"name":"David and Twila Woods Foundation"},{"name":"Faculty Career Development Award from the Gerstner Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s10620-022-07387-x","type":"journal-article","created":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T06:02:38Z","timestamp":1644040958000},"page":"5107-5115","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Germline Cancer Testing in Unselected Patients with Gastric and Esophageal Cancers: A Multi-center Prospective Study"],"prefix":"10.1007","volume":"67","author":[{"suffix":"Jr.","given":"P. L. S.","family":"Uson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. L.","family":"Kunze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Golafshar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Botrus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Riegert-Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Boardman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J.","family":"Borad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. B.","family":"Sonbol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Klint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. D.","family":"Esplin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. L.","family":"Nussbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. K.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Bekaii-Saab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7182-5569","authenticated-orcid":false,"given":"N. J.","family":"Samadder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,5]]},"reference":[{"key":"7387_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CACancer J Clin 2021;71:209\u2013249.","journal-title":"CACancer J Clin"},{"key":"7387_CR2","unstructured":"Gastric cancer. NCCN guidelines version 2.2021. In: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/gastric.pdf. Accessed 19 March 2021."},{"key":"7387_CR3","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/CEJ.0000000000000262","volume":"26","author":"JK Zhao","year":"2017","unstructured":"Zhao JK, Wu M, Kim CH et al. Jiangsu Four Cancers Study: A large case-control study of lung, liver, stomach and esophageal cancers in Jiangsu Province. China. Eur J Cancer Prev 2017;26:357\u2013364.","journal-title":"China. Eur J Cancer Prev"},{"key":"7387_CR4","first-page":"591","volume":"19","author":"A Yusefi","year":"2018","unstructured":"Yusefi A, Lankarani KB, Bastani P, Radinmanesh M, Kavosi Z. Risk factors for gastric cancer: a systematic review. Asian Pac J Cancer Prev 2018;19:591\u2013603.","journal-title":"Asian Pac J Cancer Prev"},{"key":"7387_CR5","doi-asserted-by":"publisher","first-page":"84459","DOI":"10.18632\/oncotarget.20880","volume":"8","author":"Z He","year":"2017","unstructured":"He Z, Zhao TT, Xu HM et al. Association between alcohol consumption and the risk of gastric cancer: a meta-analysis of prospective cohort studies. Oncotarget 2017;8:84459\u201384472.","journal-title":"Oncotarget"},{"key":"7387_CR6","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1001\/jamaoncol.2019.1208","volume":"5","author":"ME Roberts","year":"2019","unstructured":"Roberts ME, Ranola JMO, Marshall ML et al. Comparison of CDH1 penetrance estimates in clinically ascertained families vs families ascertained for multiple gastric cancers. JAMA Oncol 2019;5:1325\u20131331.","journal-title":"JAMA Oncol"},{"key":"7387_CR7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2147\/CMAR.S149619","volume":"10","author":"R Sitarz","year":"2018","unstructured":"Sitarz R, Skierucha M, Mielko J, Offerhaus GJA, Maciejewski R, Polkowski WP. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res 2018;10:239\u2013248.","journal-title":"Cancer Manag Res"},{"key":"7387_CR8","unstructured":"National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. Cancer Stat Facts: Stomach Cancer. 2020. In: https:\/\/seer.cancer.gov\/statfacts\/html\/stomach.html. Accessed 19 March 2021."},{"key":"7387_CR9","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1093\/aje\/kwm051","volume":"165","author":"ND Freedman","year":"2017","unstructured":"Freedman ND, Abnet CC, Leitzmann MF et al. A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am J Epidemiol 2017;165:1424\u20131433.","journal-title":"Am J Epidemiol"},{"key":"7387_CR10","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1093\/jnci\/djg047","volume":"95","author":"LS Engel","year":"2003","unstructured":"Engel LS, Chow WH, Vaughan TL et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst 2003;95:1404\u20131413.","journal-title":"J Natl Cancer Inst"},{"key":"7387_CR11","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1093\/annonc\/mds244","volume":"24","author":"F Turati","year":"2013","unstructured":"Turati F, Tramacere I, La Vecchia C, Negri E. A meta-analysis of body mass index and esophageal and gastric cardia adenocarcinoma. Ann Oncol 2013;24:609\u2013617.","journal-title":"Ann Oncol"},{"key":"7387_CR12","unstructured":"Cossentino MJ,Wong RK. Barrett's esophagus and risk of esophageal adenocarcinoma.\u00a0Sem Gastroint Dis. Vol. 14. No. 3. 2003."},{"key":"7387_CR13","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJM199903183401101","volume":"340","author":"J Lagergren","year":"1999","unstructured":"Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825\u2013831.","journal-title":"N Engl J Med"},{"key":"7387_CR14","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1001\/jamaoncol.2020.6252","volume":"7","author":"NJ Samadder","year":"2021","unstructured":"Samadder NJ, Riegert-Johnson D, Boardman L et al. Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome. JAMA Oncol 2021;7:230\u2013237.","journal-title":"JAMA Oncol"},{"key":"7387_CR15","unstructured":"Petrucelli N, Daly MB, Pal T. BRCA1-and BRCA2-associated hereditary breast and ovarian cancer.\u00a0GeneReviews\u00ae[Internet]\u00a02016."},{"issue":"1","key":"7387_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2010.05.011","volume":"79","author":"M Nielsen","year":"2011","unstructured":"Nielsen M, Morreau H, Vasen HFA, Hes FJ. MUTYH-associated polyposis (MAP). Crit Rev Oncol Hematol 2011;79:1\u201316.","journal-title":"Crit Rev Oncol Hematol"},{"key":"7387_CR17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12916-021-01999-2","volume":"19","author":"EV Haverfield","year":"2021","unstructured":"Haverfield EV, Esplin ED, Aguilar SJ et al. Physician-directed genetic screening to evaluate personal risk for medically actionable disorders: a large multi-center cohort study. BMC Med 2021;19:199.","journal-title":"BMC Med"},{"key":"7387_CR18","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s00535-015-1093-9","volume":"50","author":"S Sugimoto","year":"2015","unstructured":"Sugimoto S, Komatsu H, Morohoshi Y, Kanai T. Recognition of and recent issues in hereditary diffuse gastric cancer. J Gastroenterol 2015;50:831\u2013843.","journal-title":"J Gastroenterol"},{"key":"7387_CR19","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1111\/j.1349-7006.2011.02038.x","volume":"102","author":"H Yamada","year":"2011","unstructured":"Yamada H, Shinmura K, Ito H et al. Germline alterations in the CDH1 gene in familial gastric cancer in the Japanese population. Cancer Sci 2011;102:1782\u20131788.","journal-title":"Cancer Sci"},{"key":"7387_CR20","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1136\/jmedgenet-2015-103094","volume":"52","author":"RS van der Post","year":"2015","unstructured":"van der Post RS, Vogelaar IP, Carneiro F et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Gen 2015;52:361\u2013374.","journal-title":"J Med Gen"},{"key":"7387_CR21","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s10689-019-00127-7","volume":"18","author":"RS van der Post","year":"2019","unstructured":"van der Post RS, Oliveira C, Guilford P, Carneiro F. Hereditary gastric cancer: What\u2019s new? Update 2013\u20132018. Fam Cancer 2019;18:363\u2013367.","journal-title":"Fam Cancer"},{"key":"7387_CR22","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1097\/GIM.0b013e31821628b6","volume":"13","author":"S Masciari","year":"2011","unstructured":"Masciari S, Dewanwala A, Stoffel EM et al. Gastric cancer in individuals with Li-Fraumeni syndrome. Genet Med 2011;13:651\u2013657.","journal-title":"Genet Med"},{"key":"7387_CR23","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1053\/j.gastro.2009.10.051","volume":"138","author":"LG Capelle","year":"2010","unstructured":"Capelle LG, Van Grieken NC, Lingsma HF et al. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology 2010;138:487\u2013492.","journal-title":"Gastroenterology"},{"key":"7387_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1001\/jamaoncol.2014.168","volume":"1","author":"S Hansford","year":"2015","unstructured":"Hansford S, Kaurah P, Li-Chang H et al. Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. JAMA Oncol 2015;1:23\u201332.","journal-title":"JAMA Oncol"},{"key":"7387_CR25","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1053\/j.gastro.2016.12.010","volume":"152","author":"R Sahasrabudhe","year":"2017","unstructured":"Sahasrabudhe R, Lott P, Bohorquez M et al. Germline mutations in PALB2, BRCA1, and RAD51C, which regulate DNA recombination repair, in patients with gastric cancer. Gastroenterol 2017;152:983\u2013986.","journal-title":"Gastroenterol"},{"key":"7387_CR26","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/sj.bjc.6600562","volume":"87","author":"A Jakubowska","year":"2002","unstructured":"Jakubowska A, Nej K, Huzarski T, Scott RJ, Lubinski J. BRCA2 gene mutations in families with aggregations of breast and stomach cancers. Br J Cancer 2002;87:888\u2013891.","journal-title":"Br J Cancer"},{"key":"7387_CR27","first-page":"60","volume":"7","author":"B Friedenson","year":"2005","unstructured":"Friedenson B. BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. Med Gen Med 2005;7:60.","journal-title":"Med Gen Med"},{"key":"7387_CR28","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S2468-1253(18)30079-7","volume":"3","author":"E Fewings","year":"2018","unstructured":"Fewings E, Larianov A, Redman J et al. Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study. Lancet Gastroenterol Hepatol 2018;3:489\u2013498.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"7387_CR29","doi-asserted-by":"publisher","DOI":"10.1200\/PO.18.00097","author":"H Ichikawa","year":"2018","unstructured":"Ichikawa H, Wakai T, Nagahashi M et al. Pathogenic germline BRCA1\/2 mutations and familial predisposition to gastric cancer. JCO Prec Oncol. 2018. https:\/\/doi.org\/10.1200\/PO.18.00097.","journal-title":"JCO Prec Oncol"},{"issue":"7","key":"7387_CR30","doi-asserted-by":"publisher","first-page":"e2114753","DOI":"10.1001\/jamanetworkopen.2021.14753","volume":"4","author":"GY Ku","year":"2021","unstructured":"Ku GY, Kemel Y, Maron SB et al. Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer. JAMA Net Open 2021;4:e2114753\u2013e2114753.","journal-title":"JAMA Net Open"},{"key":"7387_CR31","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S1470-2045(17)30682-4","volume":"18","author":"YJ Bang","year":"2017","unstructured":"Bang YJ, Xu RH, Chin K et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2017;18:1637\u20131651.","journal-title":"Lancet Oncol"},{"key":"7387_CR32","doi-asserted-by":"crossref","unstructured":"Bang YJ, Kaufman B, Geva R et al. An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in patients with relapsed gastric cancer. J Clin Oncol 2019; 37: abstr 140\u2013140.","DOI":"10.1200\/JCO.2019.37.4_suppl.140"},{"key":"7387_CR33","doi-asserted-by":"crossref","unstructured":"Cecchini M, LoRusso P, Shyr Y et al. NCI 10066: A phase 1\/2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma. J Clin Oncol 2018; 36: abstr TPS4137-TPS4137.","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS4137"},{"key":"7387_CR34","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/MEG.0b013e328344042d","volume":"23","author":"AB Varela","year":"2011","unstructured":"Varela AB, Rodr\u00edguez MMB, Boullosa PE, Silva JG. Tylosis A with squamous cell carcinoma of the oesophagus in a Spanish family. Eur J Gastroenterol Hepatol 2011;23:286\u2013288.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"7387_CR35","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1016\/j.cgh.2014.01.028","volume":"12","author":"RE Verbeek","year":"2014","unstructured":"Verbeek RE, Spittuler LF, Peute A et al. Familial clustering of Barrett\u2019s esophagus and esophageal adenocarcinoma in a European cohort. Clin Gastroenterol Hepatol 2014;12:1656\u20131663.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"7387_CR36","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1159\/000452082","volume":"8","author":"C Cunniff","year":"2017","unstructured":"Cunniff C, Bassetti JA, Ellis NA. Bloom\u2019s syndrome: clinical spectrum, molecular pathogenesis, and cancer predisposition. Mol Syndromol 2017;8:4\u201323.","journal-title":"Mol Syndromol"},{"key":"7387_CR37","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/nrc970","volume":"3","author":"AD D'Andrea","year":"2003","unstructured":"D\u2019Andrea AD, Grompe M. The Fanconi anaemia\/BRCA pathway. Nature Rev Cancer 2003;3:23\u201334.","journal-title":"Nature Rev Cancer"},{"key":"7387_CR38","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/ijc.32619","volume":"146","author":"JMY Ko","year":"2020","unstructured":"Ko JMY, Ning L, Zhao XK et al. BRCA2 loss-of-function germline mutations are associated with esophageal squamous cell carcinoma risk in Chinese. Int J Cancer 2020;146:1042\u20131051.","journal-title":"Int J Cancer"},{"key":"7387_CR39","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/sj.onc.1210739","volume":"27","author":"MR Akbari","year":"2008","unstructured":"Akbari MR, Malekzadeh R, Nasrollahzadeh D et al. Germline BRCA2 mutations and the risk of esophageal squamous cell carcinoma. Oncogene 2008;27:1290\u20131296.","journal-title":"Oncogene"},{"key":"7387_CR40","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/ng.3659","volume":"48","author":"M Secrier","year":"2016","unstructured":"Secrier M, Li X, Silva N et al. Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nat genet 2016;48:1131\u20131141.","journal-title":"Nat genet"},{"key":"7387_CR41","doi-asserted-by":"publisher","first-page":"S1191","DOI":"10.1016\/j.annonc.2020.08.2296","volume":"31","author":"M Moehler","year":"2020","unstructured":"Moehler M, Shitara K, Garrido M et al. LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer\/gastroesophageal junction cancer (GC\/GEJC)\/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study. Ann Oncol 2020;31:S1191.","journal-title":"Ann Oncol"},{"key":"7387_CR42","doi-asserted-by":"publisher","first-page":"S1142","DOI":"10.1016\/j.annonc.2020.08.2298","volume":"31","author":"K Kato","year":"2020","unstructured":"Kato K, Sun J, Shah MA et al. Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study. Ann Oncol 2020;31:S1142.","journal-title":"Ann Oncol"},{"key":"7387_CR43","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2217\/fon-2018-0354","volume":"15","author":"VG de Aguiar","year":"2019","unstructured":"de Aguiar VG, Segatelli V, Macedo ALV et al. Signet ring cell component, not the Lauren subtype, predicts poor survival: an analysis of 198 cases of gastric cancer. Future Oncol 2019;15:401\u2013408.","journal-title":"Future Oncol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-022-07387-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-022-07387-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-022-07387-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T05:14:59Z","timestamp":1666415699000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-022-07387-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,5]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["7387"],"URL":"https:\/\/doi.org\/10.1007\/s10620-022-07387-x","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,5]]},"assertion":[{"value":"14 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NJS is a consultant for Jansen Research and Development and Cancer Prevention Pharmaceuticals. EDE and RLN are employees and stockholders of Invitae. RLN is also a consultant for Pfizer and a consultant and stockholder in Genome Medical and Maze Therapeutics. No other authors have a conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}